# US 2024/0197895 A1 · Compositions and methods for treating patients with mitochondrial complex i deficiency using caspase-9 signaling pathway inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197895 A1
- Document ID: US20240197895A1
- Status: Published application
- Kind: A1
- Application number: 18/258,796
- Filed: 2021-12-14
- Published: 2024-06-20
- Earliest claimed: 2020-12-22
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Carol M. TROY; Maria I. AVRUTSKY
- Web page: https://patentgrep.com/patent/US20240197895A1

## CPC

- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/1761: {Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61P 27/02: Ophthalmic agents
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/21: containing a His-tag
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to a method for treating mitochondrial complex I deficiency comprising administering to patients with mitochondrial complex I deficiency an effective amount of XBIR3. The effective amount of XBIR 3 may be conjugated to a cell-penetrating peptide, such conjugation may include encapsulation of XBIR3 in nano-carrier that is conjugated to a cell penetrating peptide or direct conjugation of XBIR3 to a cell penetrating peptide. The XBIR-3 conjugated to a cell-penetrating peptide may be administered directly to the eye of the patient, administered systemically, or administered intranasally.

## Claims

### Claim 1

A method for treating a mitochondrial complex I deficiency, the method comprising administering to an eye containing an inner plexiform layer and a ganglion cell layer of a patient having a mitochondrial complex I deficiency an amount of a caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to a cell-penetrating peptide effective to treat the mitochondrial complex I deficiency by decreasing the amount of 4-Hydroxynonenal (4-HNE) in the inner plexiform layer of the eye of the patient by more than 5%, reducing retinal thinning by at least 5%, decreasing the amount of cl-Casp-9 in the inner plexiform layer of the eye of the patient by more than 5%, or decreasing the rate of ganglion cell death in the ganglion cell layer as measured by an improvement of 5% minimum contrast detected as measured by contrast sensitivity testing.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein administering to the eye of the patient comprises administering an eye drop comprising the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide.

### Claim 4 (depends on 1)

The method of claim 1, wherein administering to the eye of the patient comprises administering a topical ophthalmic ointment comprising the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide.

### Claim 5 (depends on 1)

The method of claim 1, wherein administering comprises administering systemically to the patient.

### Claim 6 (depends on 1)

The method of claim 1, wherein administering comprises administering via intranasal delivery to the patient.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell-penetrating peptide is selected from the group consisting of Penetratin1, transportan, pISl, Tat (48-60) , pVEC, MAP, and MTS.

### Claim 8 (depends on 1)

The method of claim 1, wherein the XBIR3 is conjugated to the cell-penetrating peptide via a disulfide bond.

### Claim at position 9

9-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the amount of the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide effective to treat the mitochondrial complex I deficiency increases the patient's acuity sensitivity by more than 10 cycle/degrees as measured by visual acuity testing.

### Claim 13 (depends on 1)

The method of claim 1, wherein the amount of the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide effective to treat the mitochondrial complex I deficiency increases the patient's contrast sensitivity as measured by an improvement of 10% minimum contrast detected as measured by contrast sensitivity testing.

### Claim 14 (depends on 1)

The method of claim 1, wherein the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide is administered at a concentration between 0.1 μM and 1,000 μM, inclusive.

### Claim 15 (depends on 1)

The method of claim 1, wherein XBIR3 is indirectly conjugated to the cell-penetrating peptide, by encapsulating XBIR3 within a nano-carrier, and the nano-carrier is conjugated to the cell-penetrating a cell penetrating peptide.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the XBIR3 has a sequence selected from the group consisting of SEQ ID NOs: 1-8.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cell-penetrating peptide has a sequence selected from the group consisting of SEQ ID NOs: 9-17.

### Claim 19 (depends on 1)

The method of claim 1, wherein the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide has a sequence selected from:
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 18)
MGSSHHHHHHSSGLVPRGSHMSTNTCLPRNPSMADYEARIFTFGTWIYSV
NKEQLARAGFYTDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRY
LLEQRGQEYINNIHLTHS;
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 19)
MGSSSSGLVPRGSHMSTNTCLPRNPSMADYEARIFTFGTWIYSVNKEQLA
RAGFYTDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRG
QEYINNIHLTHS;
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 20)
SSGLVPRGSHMSTNTCLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGF
YTDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRGQEYI
NNIHLTHS;
(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 21)
MSTNTCLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYTDWALGEGD
KVKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRGQEYINNIHLTHS;
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 22)
MGSSHHHHHHSSGLVPRGSHMSTNTLPRNPSMADYEARIFTFGTWIYSVN
KEQLARAGFYTDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRYL
LEQRGQEYINNIHLTHS;
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 23)
MGSSSSGLVPRGSHMSTNTLPRNPSMADYEARIFTFGTWIYSVNKEQLAR
AGFYTDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRGQ
EYINNIHLTHS;
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 24)
SSGLVPRGSHMSTNTLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFY
TDWALGEGDKVKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRGQEYIN
NIHLTHS;
and
C(NPys)-RQIKIWFQNRRMKWKK-s-s-
(SEQ ID NO: 25)
MSTNTLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYTDWALGEGDK
VKCFHCGGGLRPSEDPWEQHARWYPGCRYLLEQRGQEYINNIHLTHS.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cell-penetrating peptide is Penetratin1.

### Claim 21 (depends on 1)

The method of claim 1, wherein administering comprises a single dose.

### Claim 22 (depends on 1)

The method of claim 1, wherein administering comprises multiple doses.

### Claim 23 (depends on 22)

The method of claim 22, wherein the multiple doses are administered at intervals of 6 times per 24 hours, 4 times per 24 hours, 3 times per 24 hours, 2 times per 24 hours, 1 time per 24 hours, 1 time every other day, 1 time every 3 days, 1 time every 4 days, 1 time per week, 2 times per week, or 3 times per week.

### Claim 24 (depends on 1)

The method of claim 1, wherein the amount of the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide effective to treat the mitochondrial complex I deficiency decreases apoptosis in the inner plexiform layer of the patient.

### Claim 25 (depends on 1)

The method of claim 1, wherein the amount of the caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to the cell-penetrating peptide effective to treat the mitochondrial complex I deficiency increases the thickness of the inner plexiform layer of the eye.
